BioCision LLC

BURLINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2025. Management Comments "We've made significant changes across the organization and our operational turnaround is progressing as planned. Despite a challenging macro environment, we drove meaningful margin expansion through disciplined cost management and focused execution," said John Marotta, President and CEO. "With a strong balance sheet and solid cash flow, we're well positioned to capitalize on future opportunities. We remain on track to meet our full-year goals and are confident that the foundation we are building will support our long-term strategy." Third Quarter Fiscal 2025 Results - Continuing Operations Revenue was $144 million, flat year over year. Organic revenue, which excludes the impact from foreign exchange, declined 2% year over year. The year-over-year revenue performance reflects higher revenue in Multiomics, offset by lower revenue in Sample Management Solutions. Sample Management Solutions revenue was $78 million, down 4% year over year. Organic revenue declined 6%, driven by lower revenues in Core Products, particularly in Automated Stores and Cryogenic Systems, partially offset by higher revenue in Sample Storage, Clinical Biostores and Product Services. Multiomics revenue was $66 million, up 4% year over year. Organic revenue grew 3% year over year, primarily driven by growth in Next Generation Sequencing, partially offset by a year-over-year decline in Sanger Sequencing and Gene Synthesis. Summary of GAAP Earnings Results - Continuing Operations Operating loss was $0.7 million. Operating margin was (0.5%), up 440 basis points year over year. Gross margin was 47.1%, up 170 basis points year over year, mainly driven by favorable sales mix, operating efficiencies, and improved cost execution. Operating expenses were $68 million, down 6% year over year, due to lower selling, general and administrative expenses, lower research and development costs, and lower restructuring charges. Other income included $5 million of net interest income versus $8.0 million in the prior year period. Diluted EPS from continuing operations was $0.01 compared to ($0.00) in the third quarter of fiscal year 2024. Diluted EPS from discontinued operations was ($1.17) due to a non-cash impairment charge of $50 million. Total diluted EPS was ($1.15), compared to ($0.12) a year ago. Summary of Non-GAAP Earnings Results - Continuing Operations Adjusted operating income was $7.9 million. Adjusted operating margin was 5.5%, an improvement of 340 basis points year over year. Adjusted gross margin was 48.5%, up 180 basis points compared to the third quarter of fiscal 2024, primarily driven by favorable sales mix, operating efficiencies, and improved cost execution. Adjusted operating expense in the quarter was $62 million, down 4% year over year, driven by lower selling, general and administrative expenses and lower research and development costs. Adjusted EBITDA was $18 million, and Adjusted EBITDA margin was 12.3%, an improvement of 260 basis points year over year. Non-GAAP Diluted EPS was $0.19, compared to $0.14 one year ago. Cash and Liquidity as of June 30, 2025 The Company ended the quarter with a total balance of cash, cash equivalents, restricted cash and marketable securities of $565 million, which includes $15 million of cash held in discontinued operations. Operating cash flow was $26 million in the quarter. Capital expenditures were $11 million, and free cash flow (cash flow from operations less capital expenditures) was $15 million. Guidance for Continuing Operations for Full Year Fiscal 2025 The Company is reiterating its guidance for fiscal year 2025: Total organic revenue is expected to grow in the range of 3% to 5% relative to fiscal 2024. Adjusted EBITDA margin expansion is expected to be approximately 300 basis points relative to fiscal 2024. Azenta does not provide forward-looking guidance on a GAAP basis for the measures on which it provides forward-looking non-GAAP guidance as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because of the inherent difficulty in accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are dependent on various factors, are out of the company's control, or cannot be reasonably predicted. Such adjustments include, but are not limited to, transformation costs, restructuring charges, costs related to acquisitions and divestitures costs, governance-related matters, goodwill and intangible impairments, and other gains and charges that are not representative of the normal operations of the business. Conference Call and Webcast Azenta management will webcast its third quarter fiscal 2025 earnings conference call today at 8:30 a.m. Eastern Time. During the call, Company management will respond to questions concerning, but not limited to, the Company's financial performance, business conditions and industry outlook. Management's responses could contain information that has not been previously disclosed. The call will be broadcast live over the Internet and, together with presentation materials referenced on the call, will be hosted at the Investor Relations section of Azenta's website at and will be archived online on this website for convenient on-demand replay. Regulation G – Use of Non-GAAP financial Measures The Company supplements its GAAP financial measures with certain non-GAAP financial measures to provide investors a better perspective on the results of business operations, which the Company believes is more comparable to the similar analyses provided by its peers. These measures are not presented in accordance with, nor are they a substitute for, U.S. generally accepted accounting principles, or GAAP. These measures should always be considered in conjunction with appropriate GAAP measures. A reconciliation of non-GAAP measures to the most nearly comparable GAAP measures is included at the end of this release following the consolidated balance sheets and statements of operations. Certain amounts in the tables that supplement the consolidated financial statements may not sum due to rounding. All percentages are calculated using unrounded amounts. "Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934 Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Forward-looking statements include but are not limited to statements about our revenue and earnings expectations, our ability to realize margin improvement from cost reductions, and our ability to deliver financial success in the future and otherwise related to future operating or financial performance and opportunities. Factors that could cause results to differ from our expectations include the following: uncertainties in global political and economic conditions, including the imposition of additional tariffs on goods imported into the US, our ability to reduce costs effectively; the volatility of the life sciences markets the Company serves; our possible inability to meet demand for our products due to difficulties in obtaining components and materials from our suppliers in required quantities and of required quality; the inability of customers to make payments to us when due; price competition; disputes concerning intellectual property; and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstance on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release. About Azenta Life Sciences Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey. Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe, and Asia. For more information, please visit . AZENTA INVESTOR CONTACTS: Yvonne Perron Vice President, Financial Planning & Analysis and Investor Relations [email protected] Sherry Dinsmore [email protected] Notes on Non-GAAP Financial Measures - Continuing Operations Non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and should not be relied upon to the exclusion of GAAP financial measures. Management adjusts the GAAP results for the impact of amortization of intangible assets, restructuring charges, purchase price accounting adjustments and charges related to M&A, non-recurring costs related to the Company's business transformation initiatives and share repurchases to provide investors better perspective on the results of operations which the Company believes is more comparable to the similar analysis provided by its peers. Management also excludes special charges and gains, such as impairment losses, gains and losses from the sale of assets, certain tax benefits and charges, as well as other gains and charges that are not representative of the normal operations of the business. Management strongly encourages investors to review our financial statements and publicly filed reports in their entirety and not rely on any single measure. SOURCE Azenta WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. BURLINGTON, Mass., May 13, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership between GENEWIZ from Azenta Life Sciences, a global provider of multiomics and synthetic solutions services, and Form Bio, a leading artificial intelligence (AI) life sciences technology company, to enhance adeno-associated virus (AAV) gene therapy development through a fully integrated sequencing and data analysis solution. This partnership brings together GENEWIZ's industry-leading next-generation sequencing services for AAV gene therapy with Form Bio's AI- and machine learning-powered analysis pipelines. The integration of these capabilities aims to provide gene therapy developers with data-driven insights into AAV capsid contents, improving safety, efficacy, and manufacturability. GENEWIZ will provide synthesis and packaging of transgene expression cassettes, complemented by high-quality, long-read sequencing services for AAV gene therapy. Form Bio will conduct comprehensive AAV Genome Integrity Characterization using Long-read AAV Analysis (LAAVA) software, identifying key opportunities to enhance vector integrity and safety, while providing actionable insights through detailed reporting. This combination enables a streamlined process that integrates sequencing, vector design, and development workflows, ultimately reducing time and cost to reach lead candidates, accelerating the path to market for innovative therapies. "Our collaboration with Form Bio marks a major step forward in simplifying AAV gene therapy workflows," said Ginger Zhou, President at GENEWIZ. "By combining our sequencing expertise with their cutting-edge analysis, we are enabling researchers to make more informed decisions and break through traditional hurdles found in gene therapy development." "Partnering with GENEWIZ allows us to embed our genome integrity insights directly into sequencing workflows," said Andrew Busey, Co-Founder and CEO at Form Bio. "By integrating analysis earlier in the process, we're helping gene therapy developers accelerate timelines, enhance vector safety, and improve the likelihood for clinical success." The partnership will officially launch at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in May 2025, where both companies will be exhibiting (booth numbers 1711 and 1143). A poster highlighting their collaborative work "The Long and Short of It: Comparing Next Generation Sequencing Methods for Quality Control in AAV Development" will be presented on May 15, 5:30-7:00 pm EST, poster #1612. About Form Bio Form Bio delivers cutting-edge AI and computational solutions to accelerate therapeutic development in cell and gene therapy. With its proprietary FORMsightAI platform, Form Bio enables rapid in silico genome integrity characterization and optimization of nucleic acid-based therapies—streamlining lead candidate selection. By integrating AI-powered design with deep expertise in molecular biology, bioinformatics, software engineering, and data science, Form Bio empowers drug developers to enhance therapeutic safety, efficacy, and manufacturability while reducing time and costs. Form Bio is headquartered in Austin, Texas with teams and offices throughout the US. For more information, visit or follow us on LinkedIn. About Azenta Life Sciences Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey. Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit . INVESTOR CONTACTS: Yvonne Perron Vice President, Financial Planning & Analysis, and Investor Relations [email protected] Sherry Dinsmore [email protected] SOURCE Azenta, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

BURLINGTON, Mass., March 24, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced the publication of its annual Environmental, Social, & Governance ("ESG") report, highlighting the Company's ongoing commitment to advancing its strategy and actions aligned with key ESG priorities. The report includes ESG data for the Company's fiscal year ended September 30, 2024. The report offers a comprehensive look at the Company's ESG approach and showcases accomplishments in three main pillars: Environmental Protection: We understand the broad impact of our operations and the potential to impact the world. We are committed to evaluating ways to reduce our environmental footprint while continuing to expand our business. Social Impact: We are committed to making a positive impact on society, particularly in the regions where we are located and serve our customers. Responsible Operations: Our products and services enable our customers to have a significant positive impact on the world, and we are committed to ensuring the safety, quality, and reliability of our products and services. In 2024, we achieved key milestones in our ESG journey, including: Reducing our carbon footprint by achieving a ~20% reduction in Scope 1 & 2 Greenhouse Gas emissions (market-based) compared to 2022, while sourcing over 60% of our electricity from renewable sources. Advancing sustainable innovation with products like the BioArc™ Ultra, providing our customers with cutting-edge solutions for large-scale, eco-friendly sample storage. Launching Azenta PRISM, our LGBTQIA+ Employee Resource Group (ERG), to foster inclusivity, advocacy, and support for our diverse workforce. Rolling out the Azenta THRIVE platform to enhance employee well-being and engagement while expanding learning and development opportunities through LinkedIn Learning®, providing employees with access to a vast library of professional training and skill-building courses. Strengthening our commitment to sustainable procurement by training 100% of our global buyer team on sustainable sourcing and expanding our partnership with EcoVadis® to evaluate the ESG performance of over half of our Tier 1 suppliers by spend. To learn more about Azenta's commitment to ESG efforts, view the report in full at . About Azenta Life Sciences Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey. Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit . "Safe Harbor Statement" under Section 21E of the Securities Exchange Act of 1934 Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta's financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Other forward-looking statements include but are not limited to statements about our ability to meet our ESG commitments, including GHG emission targets. Factors that could cause results to differ from our expectations include the following: our ability to reduce our environmental footprint, our ability to ensure the safety, quality and reliability of our products and our ability to monitor and assess our supply chain; and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release. INVESTOR CONTACTS: Yvonne Perron Vice President, Financial Planning & Analysis, and Investor Relations [email protected] Sherry Dinsmore [email protected] SOURCE Azenta WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED